



General information about company		Notes
Scrip code	532523	-
NSE Symbol	BIOCON	-
MSEI Symbol	NOTLISTED	-
ISIN	INE376G01013	-
Name of the entity	Biocon Limited	-
Date of start of financial year	01-04-2025	-
Date of end of financial year	31-03-2026	-
Reporting Quarter Type	Yearly	-
Date of Quarter Ending	31-03-2026	-
Type of company	Equity	-
Whether Annexure I (Part A) of the SEBI Circular dated December 31, 2024 related to Compliance Report on Corporate Governance is applicable to the entity?	Yes	-
Whether Annexure I (Part B) of the SEBI Circular dated December 31, 2024 related to Investor Grievance Redressal Report is Applicable to the entity?	Yes	-
Whether Annexure I (Part C) of the SEBI Circular dated December 31, 2024 related to Disclosure of Acquisition of Shares or Voting Rights in Unlisted Companies is Applicable to the entity?	Yes	-
Whether Annexure I (Part D) of the SEBI Circular dated December 31, 2024 related to Disclosure of Imposition of Fine or Penalty is Applicable to the entity?	No	No fine or penalty is applicable for the current quarter
Whether Annexure I (Part E) of the SEBI Circular dated December 31, 2024 related to Disclosure of Updates to Ongoing Tax Litigations or Disputes is Applicable to the entity?	Yes	-
Whether Annexure I (Part F) of the SEBI Circular dated December 31, 2024 related to Disclosure Of Loans / Guarantees / Comfort Letters / Securities Etc. is Applicable to the entity?	No	No such loans/gaurantees/comfort letters/securities etc given during current quarter.
Risk management committee	Applicable	-
Market Capitalisation as per immediate previous Financial Year	Top 500 listed entities	-
Is SCORE ID Available ?	Yes	-
SCORE Registration ID	b00173	-
Reason For No SCORE ID	-	-
Type of Submission	Original	-
Remarks (website dissemination)	-	-
Remarks for Exchange (not for Website Dissemination)	-	-

**Annexure I**  
Annexure I to be submitted by listed entity on quarterly basis  
I. Composition of Board of Directors

Disclosure of notes on composition of board of directors explanatory		Note:		Disqualification of Directors under section 166 of the Companies Act, 2013																						
Whether the listed entity has a Regular Chairperson		Yes																								
Whether Chairperson is related to MD or CEO		No																								
Sr	Title (Mr/Ms)	Name of the Director	DIN	Category 1 of directors	Category 2 of directors	Category 3 of directors	Date of Birth	Whether the director is disqualified?	Start Date of disqualification	End Date of disqualification	Details of disqualification	Current status	Whether special resolution passed? (Refer Reg. 17(1A) of Listing Regulations)	Date of passing special resolution	Initial Date of appointment	Date of Re-appointment	Date of cessation	Tenure of director (in months)	No of Directorship in listed entities including this listed entity (Refer Regulation 17A(1) & reg. 17A(2))	No of Independent Directorship in listed entities including this listed entity (with reference to annex to regulation 17A(1) & reg. 17A(2))	Number of memberships in Audit/ Stakeholder Committee(s) including this listed entity (Refer Regulation 26(1) of Listing Regulations)	No of post of Chairperson in Audit/ Stakeholder Committee held in listed entities including this listed entity (Refer Regulation 26(1) of Listing Regulations)	Reason for Cessation	Notes for not providing PAN	Notes for not providing DIN	
1	Mr	Kiran Mazumdar Shaw	03147229	Executive Director	Chairperson related to Promoter		23-03-1953	No				Active	NA		01-04-2010	01-04-2025				4	1	0	0			
2	Mr	Bishnu Mittal	0230757	Executive Director	Not Applicable	CEO, MD	25-09-1978	No				Active	NA		01-12-2019	01-12-2024				1	0	0	0			
3	Mr	Rajit Rasendra Mazumdar	00109213	Non-Executive - Non Independent Director	Not Applicable		17-04-1955	No				Active	NA		08-08-2000					1	0	1	0			
4	Mr	Eric Mazumdar	09381540	Non-Executive - Non Independent Director	Not Applicable		12-01-1993	No				Active	NA		01-11-2021					1	0	0	0			
5	Mr	Bobby Karandhar Parikh	00019457	Non-Executive - Independent Director	Not Applicable		30-04-1964	No				Active	NA		27-07-2018	25-07-2025		02.05		4	3	7	3			
6	Ms	Naina Lal Kidwai	00017806	Non-Executive - Independent Director	Not Applicable		16-04-1957	No				Active	NA		28-04-2022	08-08-2025		47.04		3	3	2	1			
7	Ms	Rishu Mahendra Mehta	02788318	Non-Executive - Independent Director	Not Applicable		05-01-1959	No				Active	NA		26-07-2023	26-07-2023		32.06		1	1	1	1			
8	Mr	Nicholas Robert Hagger	08518863	Non-Executive - Independent Director	Not Applicable		25-04-1965	No				Active	NA		01-09-2023	01-09-2023		31		1	1	1	0		Nicholas Robert Hagger is a foreign director and does not have PAN.	
9	Mr	Abul Dhawan	0737372	Non-Executive - Independent Director	Not Applicable		08-09-1958	No				Active	NA		16-05-2024	16-05-2024		22.31		2	2	3	1			

\*Note: 1. The date of appointment for Mr. Kiran Mazumdar Shaw is mentioned as 01/04/2020 as per the MCA records. Please note that Mr. Kiran Mazumdar Shaw has been the Director of the Company since incorporation i.e. November 23, 1978, of initial appointment. However, in this quarter, the same has been reported including the date of her date of initial appointment.

**Annexure 1**

Disclosure of notes on composition of committees explanatory

Yes

**Audit Committee Details**

Whether the Audit Committee has a Regular Chairperson						Yes		
Sr	DIN Number	Name of Committee members	Category 1 of directors	Category 2 of directors	Date of Appointment	Date of Cessation	Remarks	
1	00019437	Bobby Kanubhai Parikh	Non-Executive - Independent Director	Chairperson	27-07-2018			
2	08518863	Nicholas Robert Haggar	Non-Executive - Independent Director	Member	01-09-2023			
3	07373372	Atul Dhawan	Non-Executive - Independent Director	Member	16-05-2024			

**Nomination and remuneration committee**

Whether the Nomination and remuneration committee has a Regular Chairperson						Yes		
Sr	DIN Number	Name of Committee members	Category 1 of directors	Category 2 of directors	Date of Appointment	Date of Cessation	Remarks	
1	00017806	Naina Lal Kidwai	Non-Executive - Independent Director	Chairperson	28-04-2022			
2	00109213	Ravi Rasendra Mazumdar	Non-Executive - Non Independent Director	Member	09-10-2015			
3	02768316	Rekha Mehrotra Menon	Non-Executive - Independent Director	Member	26-07-2023			

<b>Stakeholders Relationship Committee</b>								
Whether the Stakeholders Relationship Committee has a Regular Chairperson						Yes		
Sr	DIN Number	Name of Committee members	Category 1 of directors	Category 2 of directors	Date of Appointment	Date of Cessation	Remarks	
1	02768316	Rekha Mehrotra Menon	Non-Executive - Independent Director	Chairperson	01-09-2023			
2	00019437	Bobby Kanubhai Parikh	Non-Executive - Independent Director	Member	27-07-2018			
3	00109213	Ravi Rasendra Mazumdar	Non-Executive - Non Independent Director	Member	05-10-2015			

<b>Risk Management Committee</b>								
Whether the Risk Management Committee has a Regular Chairperson						Yes		
Sr	DIN Number	Name of Committee members	Category 1 of directors	Category 2 of directors	Date of Appointment	Date of Cessation	Remarks	
1	00019437	Bobby Kanubhai Parikh	Non-Executive - Independent Director	Chairperson	24-01-2019			
2	00347229	Kiran Mazumdar Shaw	Executive Director	Member	24-01-2019			
3	03230757	Siddhath Mittal	Executive Director	Member	01-12-2019			
4	09381549	Eric Mazumdar	Non-Executive - Non Independent Director	Member	01-11-2021			
5	08518863	Nicholas Robert Haggar	Non-Executive - Independent Director	Member	01-09-2023			
6	07373372	Atul Dhawan	Non-Executive - Independent Director	Member	16-05-2024			

Corporate Social Responsibility Committee							
Whether the Corporate Social Responsibility Committee has a Regular Chairperson					Yes		
Sr	DIN Number	Name of Committee members	Category 1 of directors	Category 2 of directors	Date of Appointment	Date of Cessation	Remarks
1	00017806	Naina Lal Kidwai	Non-Executive - Independent Director	Chairperson	28-04-2022		
2	00109213	Ravi Rasendra Mazumdar	Non-Executive - Non Independent Director	Member	05-10-2015		
3	03230757	Siddhath Mittal	Executive Director	Member	28-03-2022		
4	09381549	Eric Mazumdar	Non-Executive - Non Independent Director	Member	28-03-2022		
5	02768316	Rekha Mehrotra Menon	Non-Executive - Independent Director	Member	26-07-2023		
6	08518863	Nicholas Robert Haggard	Non-Executive - Independent Director	Member	01-09-2023		

Other Committee							
Sr	DIN Number	Name of Committee members	Name of other committee	Category 1 of directors	Category 2 of directors	Remarks	
1	00347229	Kiran Mazumdar Shaw	Fund Raising Committee	Executive Director	Member		
2	03230757	Siddhath Mittal	Fund Raising Committee	Executive Director	Member		
3	00019437	Bobby Kanubhai Parikh	Fund Raising Committee	Non-Executive - Independent Director	Member		

**Annexure 1**

<b>III. Meeting of Board of Directors</b>							
Disclosure of notes on meeting of board of directors explanatory							
<b>Sr. No.</b>	<b>Date(s) of meeting (Enter dates of Previous quarter and Current quarter in chronological order)</b>	<b>Maximum gap between any two consecutive (in number of days)</b>	<b>Notes for not providing Date</b>	<b>Whether requirement of Quorum met (Yes/No)</b>	<b>Total Number of Directors as on date of the meeting</b>	<b>Number of Directors present* (All directors including Independent Director)</b>	<b>No. of Independent Directors attending the meeting*</b>
1	01-10-2025			Yes	9	8	4
2	11-11-2025	40		Yes	9	9	5
3	06-12-2025	24		Yes	9	9	5
4	12-02-2026	67		Yes	9	9	5
5	27-03-2026	42		Yes	9	8	4

**Annexure 1**

**IV. Meeting of Committees**

Disclosure of notes on meeting of committees explanatory										
Sr	Name of Committee	Date(s) of meeting (Enter dates of Previous quarter and Current quarter in chronological order)	Maximum gap between any two consecutive (in number of days)	Name of other committee	Reason for not providing date	Whether requirement of Quorum met (Yes/No)	Total Number of Directors in the Committee as on date of the meeting	Number of Directors Present (All Directors including Independent Director)	No. of Independent Directors attending the meeting*	No. of members attending the meeting (other than Board of Directors)
1	Stakeholders Relationship Committee	10-11-2025				Yes	3	3	2	0
2	Stakeholders Relationship Committee	12-02-2026	93			Yes	3	3	2	0
3	Nomination and remuneration committee	10-11-2025				Yes	3	3	2	0
4	Nomination and remuneration committee	11-02-2026	92			Yes	3	3	2	0
5	Nomination and remuneration committee	27-03-2026	43			Yes	3	3	2	0
6	Corporate Social Responsibility Committee	10-11-2025				Yes	6	6	3	0
7	Corporate Social Responsibility Committee	11-02-2026	92			Yes	6	6	3	0
8	Risk Management Committee	10-11-2025				Yes	6	6	3	0
9	Risk Management Committee	11-02-2026	92			Yes	6	6	3	0
10	Audit Committee	11-11-2025				Yes	3	3	3	0
11	Audit Committee	06-12-2025				Yes	3	3	3	0
12	Audit Committee	11-02-2026	66			Yes	3	3	3	0

## Annexure 1

V. Affirmations		
Sr	Subject	Compliance status (Yes/No)
1	The composition of Board of Directors is in terms of SEBI (Listing obligations and disclosure requirements) Regulations, 2015	Yes
2	The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015 <b>a. Audit Committee</b>	Yes
3	The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015. <b>b. Nomination &amp; remuneration committee</b>	Yes
4	The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015. <b>c. Stakeholders relationship committee</b>	Yes
5	The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015. <b>d. Risk management committee (applicable to the top 1000 listed entities)</b>	Yes
6	The committee members have been made aware of their powers, role and responsibilities as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015.	Yes
7	The meetings of the board of directors and the above committees have been conducted in the manner as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015.	Yes
8	This report and/or the report submitted in the previous quarter has been placed before Board of Directors.	Yes

<b>Details of Cyber security incidence</b>	
Whether as per Regulation 27(2)(ba) of SEBI (LODR) Regulations, 2015 there has been cyber security incidents or breaches or loss of data or documents during the quarter	No
Other details of cyber security incidence or breaches or loss of data event	-
Number of cyber security incidence or breaches or loss of data event occurred during the quarter	-

Annexure II				
Annexure II to be submitted by listed entity at the end of the financial year (for the whole of financial year)				
I. Disclosure on website in terms of LODR Regulation				
Sr	Item	Compliance status (Yes/No/NA)	If status is "No" details of non-compliance may be given here.	Web address
<b>As per regulation 46(2) of the LODR:</b>				
1.1	Details of business	Yes		<a href="https://www.biocon.com/businesses/">https://www.biocon.com/businesses/</a>
1.2	Memorandum of Association and Articles of Association	Yes		<a href="https://www.biocon.com/docs/Memorandum-of-association-and-articles-of-association.pdf">https://www.biocon.com/docs/Memorandum-of-association-and-articles-of-association.pdf</a>
1.3	Brief profile of board of directors including directorship and full-time positions in body corporates	Yes		<a href="https://www.biocon.com/investor-relations/corporate-governance/board-of-directors/">https://www.biocon.com/investor-relations/corporate-governance/board-of-directors/</a>
2	Terms and conditions of appointment of independent directors	Yes		<a href="https://www.biocon.com/docs/Letter%20to%20Appointment%20-Template.pdf">https://www.biocon.com/docs/Letter%20to%20Appointment%20-Template.pdf</a>
3	Composition of various committees of board of directors	Yes		<a href="https://www.biocon.com/investor-relations/corporate-governance/board-committees/">https://www.biocon.com/investor-relations/corporate-governance/board-committees/</a>
4	Code of conduct of board of directors and senior management personnel	Yes		<a href="https://www.biocon.com/docs/Code-of-conduct.pdf">https://www.biocon.com/docs/Code-of-conduct.pdf</a>
5	Details of establishment of vigil mechanism/ Whistle Blower policy	Yes		<a href="https://www.biocon.com/docs/Biocon-Whistle-Blower-and-Integrity-Policy.pdf">https://www.biocon.com/docs/Biocon-Whistle-Blower-and-Integrity-Policy.pdf</a>
6	Criteria of making payments to non-executive directors	Yes		<a href="https://www.biocon.com/docs/Policy-on-Director's-appointment-and-remuneration.pdf">https://www.biocon.com/docs/Policy-on-Director's-appointment-and-remuneration.pdf</a>
7	Policy on dealing with related party transactions	Yes		<a href="https://www.biocon.com/docs/Policy-on-Related-Party-Transactions.pdf">https://www.biocon.com/docs/Policy-on-Related-Party-Transactions.pdf</a>
8	Policy for determining 'material' subsidiaries	Yes		<a href="https://www.biocon.com/docs/Policy-on-Material-Subsidiaries.pdf">https://www.biocon.com/docs/Policy-on-Material-Subsidiaries.pdf</a>
9	Details of familiarization programmes imparted to independent directors	Yes		<a href="https://www.biocon.com/docs/Familiarisation_Programme.pdf">https://www.biocon.com/docs/Familiarisation_Programme.pdf</a>
10	Email address for grievance redressal and other relevant details	Yes		<a href="https://www.biocon.com/investor-relations/contact-investors-relation/">https://www.biocon.com/investor-relations/contact-investors-relation/</a>
11	Contact information of the designated officials of the listed entity who are responsible for assisting and handling investor grievances	Yes		<a href="https://www.biocon.com/investor-relations/contact-investors-relation/">https://www.biocon.com/investor-relations/contact-investors-relation/</a>
12	Financial results	Yes		<a href="https://www.biocon.com/investor-relations/financial-information/quarterly-reports/">https://www.biocon.com/investor-relations/financial-information/quarterly-reports/</a>
13	Shareholding pattern	Yes		<a href="https://www.biocon.com/investor-relations/stock-exchange-disclosures/shareholding-pattern/">https://www.biocon.com/investor-relations/stock-exchange-disclosures/shareholding-pattern/</a>
14	Details of agreements entered into with the media companies and/or their associates	NA		
15.1	(I) Schedule of analyst or institutional investor meet (II) Presentations prepared by the listed entity for analysts or institutional investors meet, post earnings or quarterly calls prior to beginning of such events.	Yes		<a href="https://www.biocon.com/investor-relations/stock-exchange-disclosures/investors-meeting/">https://www.biocon.com/investor-relations/stock-exchange-disclosures/investors-meeting/</a>
15.2	Audio recordings, video recordings, if any, and transcripts of post earnings or quarterly calls, by whatever name called, conducted physically or through digital means	Yes		<a href="https://www.biocon.com/news-biocon/video-gallery-biocon/quarterly-statements-biocon/#1653297216088-5a4e9281-2d49">https://www.biocon.com/news-biocon/video-gallery-biocon/quarterly-statements-biocon/#1653297216088-5a4e9281-2d49</a> <a href="https://www.biocon.com/investor-relations/financial-information/earning-call-transcripts/">https://www.biocon.com/investor-relations/financial-information/earning-call-transcripts/</a>
16	New name and the old name of the listed entity	NA		
17	Advertisements as per regulation 47 (1)	Yes		<a href="https://www.biocon.com/investor-relations/stock-exchange-disclosures/newspaper-advertisement/">https://www.biocon.com/investor-relations/stock-exchange-disclosures/newspaper-advertisement/</a>
18	Credit rating or revision in credit rating obtained	Yes		<a href="https://www.biocon.com/investor-relations/stock-exchange-disclosures/other-announcements-disclosures/">https://www.biocon.com/investor-relations/stock-exchange-disclosures/other-announcements-disclosures/</a>
19	Separate audited financial statements of each subsidiary of the listed entity in respect of a relevant financial year	Yes		<a href="https://www.biocon.com/investor-relations/financial-information/subsidiary-financials/">https://www.biocon.com/investor-relations/financial-information/subsidiary-financials/</a>
20	Secretarial Compliance Report	Yes		<a href="https://www.biocon.com/investor-relations/stock-exchange-disclosures/other-announcements-disclosures/">https://www.biocon.com/investor-relations/stock-exchange-disclosures/other-announcements-disclosures/</a>
21	Materiality Policy as per Regulation 30 (4)	Yes		<a href="https://www.biocon.com/docs/Biocon_Policy-for-determining-materiality-for-disclosures.pdf">https://www.biocon.com/docs/Biocon_Policy-for-determining-materiality-for-disclosures.pdf</a>
22	Disclosure of contact details of KMP who are authorized for the purpose of determining materiality as required under regulation 30(5)	Yes		<a href="https://www.biocon.com/docs/Key-Manageial-Personnel-authorized-for-determining-materiality-of-events-and-making-disclosures.pdf">https://www.biocon.com/docs/Key-Manageial-Personnel-authorized-for-determining-materiality-of-events-and-making-disclosures.pdf</a>
23	Disclosures under regulation 30(8)	Yes		<a href="https://www.biocon.com/investor-relations/stock-exchange-disclosures/">https://www.biocon.com/investor-relations/stock-exchange-disclosures/</a>
24	Statements of deviation(s) or variations(s) as specified in regulation 32	NA		
25	Dividend Distribution policy as per Regulation 43A(1)	Yes		<a href="https://www.biocon.com/docs/Biocon_Dividend%20Distribution%20Policy_2020.pdf">https://www.biocon.com/docs/Biocon_Dividend%20Distribution%20Policy_2020.pdf</a>
26.1	Annual return as provided under section 92 of the Companies Act, 2013	Yes		<a href="https://www.biocon.com/investor-relations/shareholder-services/annual-general-meeting/">https://www.biocon.com/investor-relations/shareholder-services/annual-general-meeting/</a>
26.2	Employee Benefit scheme documents framed in terms of SEBI (SBEB) Regulations, 2021	Yes		<a href="https://www.biocon.com/docs/Biocon-LTI-RSU-Plan-2020-24.pdf">https://www.biocon.com/docs/Biocon-LTI-RSU-Plan-2020-24.pdf</a> <a href="https://www.biocon.com/docs/Biocon-LTI-RSU-Plan-2025-29.pdf">https://www.biocon.com/docs/Biocon-LTI-RSU-Plan-2025-29.pdf</a>
27	Confirmation that the above disclosures are in a separate section as specified in regulation 46(2)	Yes		<a href="https://www.biocon.com/investor-relations/disclosures-under-regulation-46-of-lodr/">https://www.biocon.com/investor-relations/disclosures-under-regulation-46-of-lodr/</a>
28	Compliance with regulation 46(3) with respect to accuracy of disclosures on the website and timely updating	Yes		<a href="https://www.biocon.com/investor-relations/disclosures-under-regulation-46-of-lodr/">https://www.biocon.com/investor-relations/disclosures-under-regulation-46-of-lodr/</a>
29	Disclosure of notes on website in terms of Listing Regulations explanatory [Text Block]			

**Annexure II**

II. Annual Affirmations				
Sr	Particulars	Regulation Number	Compliance status (Yes/No/NA)	If status is "No" details of non-compliance may be given here.
1	Independent director(s) have been appointed in terms of specified criteria of 'independence' and/or 'eligibility'	16(1)(b)	Yes	
2	Board composition	17(1), 17(1A) & 17(1C), 17(1D) & 17(1E)	Yes	
3	Meeting of Board of directors	17(2)	Yes	
4	Quorum of Board meeting	17(2A)	Yes	
5	Review of Compliance Reports	17(3)	Yes	
6	Plans for orderly succession for appointments	17(4)	Yes	
7	Code of Conduct	17(5)	Yes	
8	Fees/compensation	17(6)	Yes	
9	Minimum Information	17(7)	Yes	
10	Compliance Certificate	17(8)	Yes	
11	Risk Assessment & Management	17(9)	Yes	
12	Performance Evaluation of Independent Directors	17(10)	Yes	
13	Recommendation of Board	17(11)	Yes	
14	Maximum number of Directorships	17A	Yes	
15	Composition of Audit Committee	18(1)	Yes	
16	Meeting of Audit Committee	18(2)	Yes	
17	Role of Audit Committee and information to be reviewed by the audit committee	18(3)	Yes	
18	Composition of nomination & remuneration committee	19(1) & (2)	Yes	
19	Quorum of Nomination and Remuneration Committee meeting	19(2A)	Yes	
20	Meeting of Nomination and Remuneration Committee	19(3A)	Yes	
21	Role of Nomination and Remuneration Committee	19(4)	Yes	
22	Composition of Stakeholder Relationship Committee	20(1), 20(2) & 20(2A)	Yes	
23	Meeting of Stakeholders Relationship Committee	20(3A)	Yes	
24	Role of Stakeholders Relationship Committee	20(4)	Yes	
25	Composition and role of risk management committee	21(1),(2),(3),(4)	Yes	
26	Meeting of Risk Management Committee	21(3A)	Yes	
27	Quorum of Risk Management Committee meeting	21(3B)	Yes	
28	Gap between the meetings of the Risk Management Committee	21(3C)	Yes	
29	Vigil Mechanism	22	Yes	
30	Policy for related party Transaction	23(1), (1A), (5), (6), & (8)	Yes	
31	Prior or Omnibus approval of Audit Committee for all related party transactions	23(2), (3)	Yes	
32	Approval for material related party transactions	23(4)	Yes	
33	Disclosure of related party transactions on consolidated basis	23(9)	Yes	
34	Composition of Board of Directors of unlisted material Subsidiary	24(1)	Yes	
35	Other Corporate Governance requirements with respect to subsidiary of listed entity	24(2),(3),(4),(5) & (6)	Yes	
36	Alternate Director to Independent Director	25(1)	Yes	
37	Maximum Tenure	25(2)	Yes	
38	Appointment, Re-appointment or removal of an Independent Director through special resolution or the alternate mechanism	25(2A)	Yes	
39	Meeting of independent directors	25(3) & (4)	Yes	
40	Familiarization of independent directors	25(7)	Yes	
41	Declaration from Independent Director	25(8) & (9)	Yes	
42	Directors and Officers insurance	25(10)	Yes	
43	Confirmation with respect to appointment of Independent Directors who resigned from the listed entity	25(11)	NA	
44	Memberships in Committees	26(1)	Yes	
45	Affirmation with compliance to code of conduct from members of Board of Directors and Senior management personnel	26(3)	Yes	
46	Policy with respect to Obligations of directors and senior management	26(2) & 26(5)	Yes	
47	Approval of the Board and shareholders for compensation or profit sharing in connection with dealings in the securities of the listed entity	26(6)	NA	
48	Vacancies in respect Key Managerial Personnel	26A(1) & 26A(2), 26A(3)	Yes	

<b>Annexure II</b>		
<b>III. Affirmations</b>		
<b>Sr</b>	<b>Particulars</b>	<b>Compliance status (Yes/No/NA)</b>
1	The Listed Entity has approved Material Subsidiary Policy and the Corporate Governance requirements with respect to subsidiary of Listed Entity have been complied	Yes
<b>Any other information to be provided</b>		

<b>Annexure II</b>		
1	Name of signatory	Rajesh U. Shanoy
2	Designation	Company Secretary and Compliance Officer

<b>Signatory Details</b>	
<b>Name of signatory</b>	Rajesh U. Shanoy
<b>Designation of person</b>	Company Secretary and Compliance Officer
<b>Place</b>	Bengaluru
<b>Date</b>	24-04-2026

### Investor Grievance Details

No. of investor complaints pending at the beginning of Quarter	3
No. of investor complaints received during the Quarter	28
No. of investor complaints disposed off during the Quarter	30
No. of investor complaints those remaining unresolved at the end of the Quarter	1

Disclosure of Acquisition of Shares or Voting Rights in Unlisted Companies-					
Any Other Information for Disclosure of Acquisition of Shares or Voting Rights in Unlisted Companies					Note*
Sr. No.	Name of the unlisted company in which shares or voting rights have been acquired	Date of acquisition	Aggregate holding (% shares or voting rights) as at the end of the previous quarter	% shares or voting rights acquired during the quarter	Aggregate holding (% shares or voting rights) as at the end of the quarter
1	Ananthapur Energy Projects Private Limited	06-02-2026	0.00%	6.12%	6.12%
<p><b>*Note : The Board of Directors of the Company has, on February 12, 2026, approved acquisition upto 15.91% of paid-up share capital of M/s AMPIN C&amp;I Power Twelve Private Limited as an investment in Special Purpose Vehicle for generation and supply of solar power to the Company. No acquisition has been made during the current quarter.</b></p>					

**Disclosure of Updates to Ongoing Tax Litigations or Disputes**  
**The updates on tax litigations or disputes in terms of sub-para 8 of para B of Part A of Schedule III read with corresponding provisions of Annexure 18 of the Master Circular are given below:**

**Any Other Information for Disclosure of Updates to Ongoing Tax Litigations or Disputes**

<b>Sr. No.</b>	<b>Name of the opposing party</b>	<b>Date of initiation of the litigation / dispute</b>	<b>Status of the litigation / dispute as per last disclosure</b>	<b>Current status of the litigation / dispute</b>
1	Deputy Commissioner, DGSTO-4, Bengaluru	22-02-2024	The Company has received an Order of Adjudication from the Deputy Commissioner of Commercial Taxes, (Audit) - 4.7, Divisional Goods and Service Tax Office - VTK-2, Bangalore under applicable provisions of the Karnataka Goods and Services Tax Act, 2017, read with rules therein, Central Goods and Services Tax Act, 2017, the Integrated Goods and Services Tax Act, 2017 and Goods and Services Tax (Compensation) Act, 2017. The demand is raised in relation to input tax credit reporting error in GST monthly return, denial of input tax credit on sales and promotional expenditures, valuation of Corporate guarantee services under GST Law, and denial of exemption on export of services. The Company is in the process of taking appropriate actions, including but not limited to, filing of necessary appeal with the appellate authority(s) in this regard. A Writ Petition was filed before the Hon'ble High Court of Karnataka against the order. The Court has admitted the Appeal and granted stay. The personal hearing scheduled on 12.12.2025 was attended and the matter was argued on behalf of the Company. Awaiting for final order.	There is no update to the litigation/dispute since the disclosure made in the last quarter.
2	Joint Commissioner of Income-Tax	25-01-2016	The Company has pending litigation with the Income Tax Department for AY 2011-12. The Order Giving Effect ('OGE') to Income Tax Appellate Tribunal order is awaited.	As the OGE proceedings are time barred and no OGE to Income Tax Appellate Tribunal ('ITAT') order is received till date, the company has filed writ petition before High Court ('HC'). The HC has stayed the OGE proceedings and detailed hearing is awaited.
3	Assistant Commissioner of Income Tax (ACIT)	31-12-2018	Biocon Biologics Limited, a Subsidiary of the Company, has pending litigation for AY 2016-2017 and is awaiting the hearing to be scheduled by the Commissioner of Income Tax Appeals (CIT(A)). Biocon Biologics Limited has been awaiting the hearing to be scheduled by the Commissioner of Income Tax Appeals (CIT(A)).	There is no update to the litigation/dispute since the disclosure made in the last quarter.
4	Deputy Commissioner of Commercial Taxes, DGSTO-4, Bengaluru	24-09-2025	The Company has received a Show Cause notice from the Deputy Commissioner of Commercial Taxes, (Audit) - 4.7, Divisional Goods and Service Tax Office - VTK-2, Bangalore under applicable provisions of the Karnataka Goods and Services Tax Act, 2017, read with rules therein, Central Goods and Services Tax Act, 2017, the Integrated Goods and Services Tax Act, 2017 and Goods and Services Tax (Compensation) Act, 2017. The proposed demand is raised in relation to credit note related turnover wrongly reduced from taxable turnover, short declaration of outward supplies in monthly returns, Credit note on Exports, interest and penalty on wrong claim of lower tax on merchant export benefits, non-payment of tax on Corporate Guarantee, delayed payment to suppliers beyond 180 days, Input tax credit mis-match between monthly returns (GSTR -3B) vis-À-vis input tax credit reported by suppliers (GSTR 2-B). The Company has received a demand order dated 23/12/2025, confirming the demand of Rs. 1.73 Crores. The Company is in the process of evaluating and filing the appeal in this matter.	Appeal filed before Joint Commissioner (Appeals) on 23/03/2026